Pharmaceuticals
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.
SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointedRegis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, ...
2023-02-08 16:05
3362
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
WILMINGTON, Del., Feb. 6, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's inves...
2023-02-06 21:10
2430
Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb
SAN DIEGO, SHANGHAI and SYDNEY, Feb. 6, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announced that the U.S. Food and Drug Administration (FDA) recently granted the initial investigational new drug (IND) application for its drug candidate IMG-008, a long-acting anti-IL-36R antib...
2023-02-06 18:00
2905
Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
* Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstratesclinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; * Clinically meaningful improvements were reported in CRISS (the key compos...
2023-02-06 13:01
2714
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial
- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks - Development of treatment for pulmonary fibrosis which is unsatisfactory and in high demand, and anticipation for extended adaptability against various rare fibrosis diseases SEOUL, South Korea, Fe...
2023-02-06 13:00
2586
Briggs wins "National Manufacturing Award 2022" at Make UK, UK's leading Manufacturer's Organization
HONG KONG, Feb. 2, 2023 /PRNewswire/ -- CIMC Enric Holdings Limited ("CIMC Enric")and its subsidiaries (collectively, the "Company") (Hong Kong stock code: 3899.HK) are pleased to announce that, Briggs of Burton PLC ("Briggs"), a subsidiary of CIMC Enric's liquid food business, has been awarded t...
2023-02-03 13:54
4486
SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan
TOKYO, Feb. 2, 2023 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused Ultrasound (HIFU)...
2023-02-02 14:00
2516
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout inChina expected in 2023 * Top-line data from tanfanercept's Phase 3 dry eye study e...
2023-02-01 20:00
2608
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche L...
2023-01-31 21:50
4335
Global Times: 'So much better than we had anticipated': China's rural regions embrace Spring Festival as COVID peak ebbs away
BEIJING, Jan. 31, 2023 /PRNewswire/ -- The Spring Festival is rooted in agricultural civilization. Chinese people believe the most traditional atmosphere of Spring Festival is in rural regions. Since the prevention and control of the COVID-19 epidemic has entered a new stage, questions have been...
2023-01-31 21:41
3062
Zhongchao Inc. Announces Introduction of Indian Anti-influenza Drugs to China
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang...
2023-01-31 20:30
2645
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
Highlights: * Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment inAustralia, the United States, and Italy * Presented compelling bioMUSE data at two prestigious industry conferences * Granted a 20-year patent for 100 new compounds targeting Parkinson's...
2023-01-31 20:25
5235
Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd (Oricell), an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, today announced publication of data from a clinical study evaluating the efficacy of OriCAR-017, an autolog...
2023-01-31 09:24
3115
Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China
BEIJING, Jan. 30, 2023 /PRNewswire/ -- Help Therapeutics Co., Ltd. (hereinafter Help Therapeutics) has revealed that the China Center for Drug Evaluation (CDE) has approved the investigational new drug (IND) application of HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in p...
2023-01-30 23:00
3100
Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases
SHANGHAI, Jan. 29, 2023 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI specially ...
2023-01-30 10:00
2797
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results
* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion. * FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit ofKRW 983.6 billion. * Strong growth momentum expected to continue with active expansions in capacity, geography, an...
2023-01-27 14:52
4632
SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane
* First Generic of Abraxane in Korea, World 4th Commercial Scale-Up * Global tech-transfer expected to US, Japan, and Europe SEONGNAM, South Korea ,Jan. 26, 2023 /PRNewswire/ -- SN BioScience (CEO Park Young-hwan) and Boryeong (CEOJang Doo-hyun) signed a domestic manufacturing technology transf...
2023-01-26 14:31
3114
iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax
* Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack * Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit * Further developments are planned to conduct with a licensing/col...
2023-01-26 10:34
2652
Singleron launches single cell eQTL analysis as part of their sequencing service
A new bioinformatic pipeline to investigate single cell eQTL analysis is now
offered in the sequencing service from Singleron Biotechnologies.
COLOGNE, Germany, Jan. 25, 2023 /PRNewswire/ -- Bioinformatic experts at
Singleron Biotechnologies
2023-01-25 19:00
2641
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI
SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thata poster presentation highlighting the Phase 1 preliminary result...
2023-01-20 21:50
5468
Week's Top Stories
Most Reposted
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00Most Read
FinVolution and NUS Business School share project findings focusing on Financial Inclusion for Filipino Overseas Domestic Helpers at UN Global Compact BRI Summit
2026-09-04 13:11
11649
Physical AI Firm XTEND Set to Make NYSE Trading Debut: NYSE Content Update
2026-09-04 21:14
10775
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
2026-09-04 10:43
8315
DAHON TECH Announces 2026 Interim Results; Revenue and Profit Record Strong Growth
2026-09-04 16:09
7941